Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Massively parallel functional testing of MSH2 missense variants conferring Lynch Syndrome risk

ABSTRACT: We performed a massively parallel screen in human HAP1 cells to identify loss-of-function missense variants in the key DNA mismatch repair factor MSH2. Resulting variant loss-of-function (LOF) scores are strongly concordant with previous functional evidence and available variant classification.

ORGANISM(S): Homo sapiens

PROVIDER: GSE162130 | GEO | 2020/12/23

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Massively parallel functional testing of MSH2 missense variants conferring Lynch syndrome risk.

Project description:The lack of functional evidence for the majority of missense variants limits their clinical interpretability and poses a key barrier to the broad utility of carrier screening. In Lynch syndrome (LS), one of the most highly prevalent cancer syndromes, nearly 90% of clinically observed missense variants are deemed "variants of uncertain significance" (VUS). To systematically resolve their functional status, we performed a massively parallel screen in human cells to identify loss-of-function missense variants in the key DNA mismatch repair factor MSH2. The resulting functional effect map is substantially complete, covering 94% of the 17,746 possible variants, and is highly concordant (96%) with existing functional data and expert clinicians' interpretations. The large majority (89%) of missense variants were functionally neutral, perhaps unexpectedly in light of its evolutionary conservation. These data provide ready-to-use functional evidence to resolve the ∼1,300 extant missense VUSs in MSH2 and may facilitate the prospective classification of newly discovered variants in the clinic.

| S-EPMC7820803 | biostudies-literature

Massively parallel functional testing of MSH2 missense variants conferring Lynch Syndrome risk

Project description:Massively parallel functional testing of MSH2 missense variants conferring Lynch Syndrome risk

| PRJNA680712 | ENA

Msh2-Lynch

Project description:Msh2-Lynch

| PRJEB45308 | ENA

Burkholderia sp. MSh2

Project description:Burkholderia sp. MSh2 Genome sequencing and assembly

| PRJNA251789 | ENA

Gene expression analysis of leukemia-initiating cells of compound URE-/+::Msh2-/- mice

Project description:Expression profiling of FACS purified Lin-cKit+ cells from compound URE-/+::Msh2-/- mice with AML and control animals Analysis of gene expression in Lin-cKit+ cells from three URE-/+::Msh2-/- mice and four wild type controls

2015-09-07 | E-GEOD-65668 | biostudies-arrayexpress

Massively-parallel functional characterization of MAPK1 missense mutants

Project description:Genome-directed oncology has the potential to revolutionize patient treatment, but is limited by an abundance of rare, uncharacterized and therapeutically uninformative somatic variants. To accelerate characterization of the “long tail” of rare somatic variants, we quantified the activity and drug responsiveness of virtually all possible (99.84%) missense variants in the Ser/Thr kinase MAPK1/ERK2. We identified recurrent and rare hypermorphic and loss-of-function alleles, revealing that variant activity is uncorrelated with mutational frequency. Somatic ERK2 variants displayed variable responses to RAF-, MEK- and ERK-directed therapies, potentially informing clinical treatment strategies for patients whose tumors harbor these alterations. A subset of recurrent and rare somatic variants co-localized on ERK2 protein-protein interfaces, yet engendered contrasting phenotypes based on their specific sub-domain localization. The approach presented here represents an allele-characterization framework that compliments existing computational efforts and supports current and future somatic variant discovery efforts, advancing the promise of genome-guided treatment strategies.

2017-12-01 | GSE79989 | GEO

Identifying crossover locations in Arabidopsis thaliana wild type Col x CLC, msh2 Col x CLC and msh2 Col x Ler F2 populations using genotyping by sequencing.

Project description:Genomic DNA from 189 wild type Col x CLC, 191 msh2 Col x CLC or 187 msh2 Col x Ler F2 individuals was extracted using CTAB and used to generate sequencing libraries as described (Serra et al 2018 PNAS). Sequencing data was analysed to identify crossovers as previously reported, using the TIGER pipeline (Rowan et al., 2015 G3).

2020-09-02 | E-MTAB-8252 | biostudies-arrayexpress

Gene expression analysis of leukemia-initiating cells of preleukemic compound URE-/+::Msh2-/- mice

Project description:Expression profiling of FACS purified Lin-cKit+ cells from preleukemic compound URE-/+::Msh2-/- mice and control animals (two separate pools of 3 mice each) Analysis of gene expression in Lin-cKit+ cells from two URE-/+::Msh2-/- mice and wild type control animals (two pools of three animals each)

2015-09-07 | E-GEOD-65669 | biostudies-arrayexpress

Gene expression analysis of leukemia-initiating cells of compound URE-/+::Msh2-/- mice

Project description:Expression profiling of FACS purified Lin-cKit+ cells from compound URE-/+::Msh2-/- mice with AML and control animals

2015-09-07 | GSE65668 | GEO

Functional interrogation of Lynch syndrome-associated MSH2 missense variants via CRISPR-Cas9 gene editing in human embryonic stem cells.

Project description:Lynch syndrome (LS) predisposes patients to cancer and is caused by germline mutations in the DNA mismatch repair (MMR) genes. Identifying the deleterious mutation, such as a frameshift or nonsense mutation, is important for confirming an LS diagnosis. However, discovery of a missense variant is often inconclusive. The effects of these variants of uncertain significance (VUS) on disease pathogenesis are unclear, though understanding their impact on protein function can help determine their significance. Laboratory functional studies performed to date have been limited by their artificial nature. We report here an in-cellulo functional assay in which we engineered site-specific MSH2 VUS using clustered regularly interspaced short palindromic repeats-Cas9 gene editing in human embryonic stem cells. This approach introduces the variant into the endogenous MSH2 loci, while simultaneously eliminating the wild-type gene. We characterized the impact of the variants on cellular MMR functions including DNA damage response signaling and the repair of DNA microsatellites. We classified the MMR functional capability of eight of 10 VUS providing valuable information for determining their likelihood of being bona fide pathogenic LS variants. This human cell-based assay system for functional testing of MMR gene VUS will facilitate the identification of high-risk LS patients.

| S-EPMC6810757 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data